Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway

Yiying Wang, Yue Wang, Zhenbo Zhang, Ji Young Park, Donghui Guo, Hong Liao, Xiaofang Yi, Yu Zheng, Donna Zhang, Setsuko K. Chambers, Wenxin Zheng

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Progestin resistance is a main obstacle for endometrial precancer/cancer conservative therapy. Therefore, biomarkers to predict progestin resistance and studies to gain a more detailed understanding of the mechanism are needed. The antioxidant Nrf2-AKR1C1 signal pathway exerts chemopreventive activity. However whether it plays a role in progestin resistance has not been explored. In this study, elevated levels of AKR1C1 and Nrf2 were found in progestin-resistant endometrial epithelia, but not in responsive endometrial glands. Exogenous overexpression of Nrf2/AKR1C1 resulted in progestin resistance. Inversely, silencing of Nrf2 or AKR1C1 rendered endometrial cancer cells more susceptible to progestin treatment. Moreover, medroxyprogesterone acetate withdrawal resulted in suppression of Nrf2/AKR1C1 expression accompanied by a reduction of cellular proliferative activity. In addition, brusatol and metformin overcame progestin resistance by down-regulating Nrf2/AKR1C1 expression. Our findings suggest that overexpression of Nrf2 and AKR1C1 in endometrial precancer/cancer may be part of the molecular mechanisms underlying progestin resistance. If validated in a larger cohort, overexpression of Nrf2 and AKR1C1 may prove to be useful biomarkers to predict progestin resistance. Targeting the Nrf2/AKR1C1 pathway may represent a new therapeutic strategy for treatment of endometrial hyperplasia/cancer.

Original languageEnglish (US)
Pages (from-to)10363-10372
Number of pages10
JournalOncotarget
Volume7
Issue number9
DOIs
StatePublished - Jan 1 2016

Fingerprint

Progestins
Endometrial Neoplasms
Biomarkers
Endometrial Hyperplasia
Medroxyprogesterone Acetate
Metformin
Signal Transduction
Therapeutics
Epithelium
Antioxidants

Keywords

  • AKR1C1
  • Endometrial cancer
  • Nrf2
  • Progestin resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. / Wang, Yiying; Wang, Yue; Zhang, Zhenbo; Park, Ji Young; Guo, Donghui; Liao, Hong; Yi, Xiaofang; Zheng, Yu; Zhang, Donna; Chambers, Setsuko K.; Zheng, Wenxin.

In: Oncotarget, Vol. 7, No. 9, 01.01.2016, p. 10363-10372.

Research output: Contribution to journalArticle

Wang, Y, Wang, Y, Zhang, Z, Park, JY, Guo, D, Liao, H, Yi, X, Zheng, Y, Zhang, D, Chambers, SK & Zheng, W 2016, 'Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway', Oncotarget, vol. 7, no. 9, pp. 10363-10372. https://doi.org/10.18632/oncotarget.7004
Wang, Yiying ; Wang, Yue ; Zhang, Zhenbo ; Park, Ji Young ; Guo, Donghui ; Liao, Hong ; Yi, Xiaofang ; Zheng, Yu ; Zhang, Donna ; Chambers, Setsuko K. ; Zheng, Wenxin. / Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. In: Oncotarget. 2016 ; Vol. 7, No. 9. pp. 10363-10372.
@article{9b2aaaf8122f4cee82e9616834e03bc2,
title = "Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway",
abstract = "Progestin resistance is a main obstacle for endometrial precancer/cancer conservative therapy. Therefore, biomarkers to predict progestin resistance and studies to gain a more detailed understanding of the mechanism are needed. The antioxidant Nrf2-AKR1C1 signal pathway exerts chemopreventive activity. However whether it plays a role in progestin resistance has not been explored. In this study, elevated levels of AKR1C1 and Nrf2 were found in progestin-resistant endometrial epithelia, but not in responsive endometrial glands. Exogenous overexpression of Nrf2/AKR1C1 resulted in progestin resistance. Inversely, silencing of Nrf2 or AKR1C1 rendered endometrial cancer cells more susceptible to progestin treatment. Moreover, medroxyprogesterone acetate withdrawal resulted in suppression of Nrf2/AKR1C1 expression accompanied by a reduction of cellular proliferative activity. In addition, brusatol and metformin overcame progestin resistance by down-regulating Nrf2/AKR1C1 expression. Our findings suggest that overexpression of Nrf2 and AKR1C1 in endometrial precancer/cancer may be part of the molecular mechanisms underlying progestin resistance. If validated in a larger cohort, overexpression of Nrf2 and AKR1C1 may prove to be useful biomarkers to predict progestin resistance. Targeting the Nrf2/AKR1C1 pathway may represent a new therapeutic strategy for treatment of endometrial hyperplasia/cancer.",
keywords = "AKR1C1, Endometrial cancer, Nrf2, Progestin resistance",
author = "Yiying Wang and Yue Wang and Zhenbo Zhang and Park, {Ji Young} and Donghui Guo and Hong Liao and Xiaofang Yi and Yu Zheng and Donna Zhang and Chambers, {Setsuko K.} and Wenxin Zheng",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.7004",
language = "English (US)",
volume = "7",
pages = "10363--10372",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway

AU - Wang, Yiying

AU - Wang, Yue

AU - Zhang, Zhenbo

AU - Park, Ji Young

AU - Guo, Donghui

AU - Liao, Hong

AU - Yi, Xiaofang

AU - Zheng, Yu

AU - Zhang, Donna

AU - Chambers, Setsuko K.

AU - Zheng, Wenxin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Progestin resistance is a main obstacle for endometrial precancer/cancer conservative therapy. Therefore, biomarkers to predict progestin resistance and studies to gain a more detailed understanding of the mechanism are needed. The antioxidant Nrf2-AKR1C1 signal pathway exerts chemopreventive activity. However whether it plays a role in progestin resistance has not been explored. In this study, elevated levels of AKR1C1 and Nrf2 were found in progestin-resistant endometrial epithelia, but not in responsive endometrial glands. Exogenous overexpression of Nrf2/AKR1C1 resulted in progestin resistance. Inversely, silencing of Nrf2 or AKR1C1 rendered endometrial cancer cells more susceptible to progestin treatment. Moreover, medroxyprogesterone acetate withdrawal resulted in suppression of Nrf2/AKR1C1 expression accompanied by a reduction of cellular proliferative activity. In addition, brusatol and metformin overcame progestin resistance by down-regulating Nrf2/AKR1C1 expression. Our findings suggest that overexpression of Nrf2 and AKR1C1 in endometrial precancer/cancer may be part of the molecular mechanisms underlying progestin resistance. If validated in a larger cohort, overexpression of Nrf2 and AKR1C1 may prove to be useful biomarkers to predict progestin resistance. Targeting the Nrf2/AKR1C1 pathway may represent a new therapeutic strategy for treatment of endometrial hyperplasia/cancer.

AB - Progestin resistance is a main obstacle for endometrial precancer/cancer conservative therapy. Therefore, biomarkers to predict progestin resistance and studies to gain a more detailed understanding of the mechanism are needed. The antioxidant Nrf2-AKR1C1 signal pathway exerts chemopreventive activity. However whether it plays a role in progestin resistance has not been explored. In this study, elevated levels of AKR1C1 and Nrf2 were found in progestin-resistant endometrial epithelia, but not in responsive endometrial glands. Exogenous overexpression of Nrf2/AKR1C1 resulted in progestin resistance. Inversely, silencing of Nrf2 or AKR1C1 rendered endometrial cancer cells more susceptible to progestin treatment. Moreover, medroxyprogesterone acetate withdrawal resulted in suppression of Nrf2/AKR1C1 expression accompanied by a reduction of cellular proliferative activity. In addition, brusatol and metformin overcame progestin resistance by down-regulating Nrf2/AKR1C1 expression. Our findings suggest that overexpression of Nrf2 and AKR1C1 in endometrial precancer/cancer may be part of the molecular mechanisms underlying progestin resistance. If validated in a larger cohort, overexpression of Nrf2 and AKR1C1 may prove to be useful biomarkers to predict progestin resistance. Targeting the Nrf2/AKR1C1 pathway may represent a new therapeutic strategy for treatment of endometrial hyperplasia/cancer.

KW - AKR1C1

KW - Endometrial cancer

KW - Nrf2

KW - Progestin resistance

UR - http://www.scopus.com/inward/record.url?scp=84961665623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961665623&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7004

DO - 10.18632/oncotarget.7004

M3 - Article

VL - 7

SP - 10363

EP - 10372

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -